A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma (NCT05827016)

🧪 Interventions in This Study

• Iberdomide (DRUG)
• Lenalidomide (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (271 Sites)

Showing the first 25 of 271 sites.

• Rocky Mountain Cancer Centers — Aurora, Colorado
• Mayo Clinic Hospital - Florida — Jacksonville, Florida
• Local Institution - 0308 — Tampa, Florida
• H. Lee Moffitt Cancer Center & Research Institute — Tampa, Florida
• Cleveland Clinic — Weston, Florida
• University Cancer & Blood Center — Athens, Georgia
• The Winship Cancer Institute of Emory University — Atlanta, Georgia
• Augusta University - Georgia Cancer Center — Augusta, Georgia
• Local Institution - 0237 — Chicago, Illinois
• University of Kansas Cancer Center - The Richard and Annette Bloch Cancer Care Pavilion — Westwood, Kansas
• Maryland Oncology Hematology, PA- Clinton — Clinton, Maryland
• UMass Memorial Medical Center — Worcester, Massachusetts
• University of Michigan - Rogel Cancer Center — Ann Arbor, Michigan
• Henry Ford Health System - The Henry Ford Cancer Institute (HFCI) - Detroit — Detroit, Michigan
• Cancer & Hematology Centers of Western Michigan (CHCWM) — Grand Rapids, Michigan
• Mayo Clinic Cancer Center (MCCC) - Rochester — Rochester, Minnesota
• Hattiesburg Clinic - Hematology & Oncology — Hattiesburg, Mississippi
• Morristown Medical Center — Morristown, New Jersey
• Perlmutter Cancer Center - Sunset Park — Brooklyn, New York
• Perlmutter Cancer Center at NYU Langone Hematology Oncology Associates-Mineola — Mineola, New York
• NYU Langone Health — New York, New York
• Columbia University Medical Center - Herbert Irving Pavilion Location — New York, New York
• Optum Medical Care PC — Westbury, New York
• Levine Cancer Institute — Charlotte, North Carolina
• Novant Health Cancer Institute - Elizabeth — Charlotte, North Carolina

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Multiple Myeloma

• Ixazomib + Pomalidomide + Dexamethasone In MM — Boston, Massachusetts
• A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma — Birmingham, Alabama
• Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant — Tampa, Florida
• MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb — Beverly Hills, California
• A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma — Phoenix, Arizona
• A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma — Hackensack, New Jersey

Explore by condition: All Multiple Myeloma clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.